Your browser doesn't support javascript.
loading
Clinical trials and evaluation of Chinese patent medicine for influenza / 中国中药杂志
China Journal of Chinese Materia Medica ; (24): 2338-2342, 2022.
Article in Chinese | WPRIM | ID: wpr-928113
ABSTRACT
The clinical randomized controlled trial(RCT) of Chinese patent medicine in the treatment of influenza were reviewed and analyzed to provide basic information for clinical decision and related research. On the basis of the collection in the Traditional Chinese Medicine(TCM) Clinical Evidence Database System(EVDS), CNKI, Wanfang, VIP, SinoMed, EMbase, PubMed, and Cochrane Library were searched for RCTs of Chinese patent medicine for influenza published from database inception to July 25, 2021. The publication time, sample size, intervention and control measures, course of treatment, outcome indicators, and methodological quality of the trials were analyzed and evaluated. Ninety-two RCTs of Chinese patent medicine for influenza published between 2005 and 2021, were included, among which 17 RCTs(18.48%) had a sample size higher than 200 and the average sample size was about 145. Twenty-seven Chinese patent medicines were involved, including twenty-one oral medicines and six injections. The Chinese patent medicines in trials reported in more than five papers included Lianhua Qingwen Capsules/Gra-nules, Tanreqing Injection, and Reduning Injection. Fourteen intervention protocols were reported, of which Chinese patent medicine+western medicine+conventional treatment vs western medicine+conventional treatment(20.65%) was the most frequently employed. Additionally, 85.87% of the RCTs reported the course of treatment, and 80.43% of the RCTs determined 3-7 d as the intervention course. Forty-five outcome indicators were extracted, which were used 434 times, including symptoms/signs, physicochemical detection, safety events, TCM symptoms/syndromes, quality of life, long-term prognosis, and economic evaluation. Symptoms/signs(61.52%) exhibited the highest frequency. Methodological problems were prevalent in the included trials. The findings reveal that there are few clinical trials on influenza treatment by Chinese patent medicine, and the methodological problems are prominent, affec-ting the reliability and practicability of the trials. In the future research, the value characteristics of Chinese patent medicine should be highlighted and the quality control in the whole process should be strengthened based on the scientific and rigorous design.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Quality of Life / Drugs, Chinese Herbal / China / Reproducibility of Results / Clinical Trials as Topic / Nonprescription Drugs / Influenza, Human / Medicine, Chinese Traditional Type of study: Controlled clinical trial / Diagnostic study / Practice guideline / Prognostic study Limits: Humans Country/Region as subject: Asia Language: Chinese Journal: China Journal of Chinese Materia Medica Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Quality of Life / Drugs, Chinese Herbal / China / Reproducibility of Results / Clinical Trials as Topic / Nonprescription Drugs / Influenza, Human / Medicine, Chinese Traditional Type of study: Controlled clinical trial / Diagnostic study / Practice guideline / Prognostic study Limits: Humans Country/Region as subject: Asia Language: Chinese Journal: China Journal of Chinese Materia Medica Year: 2022 Type: Article